166 related articles for article (PubMed ID: 37066770)
1. Exploration of Novel PDEδ Inhibitor Based on Pharmacophore and Molecular Docking against KRAS Mutant in Colorectal Cancer.
Mouhcine M; Kadil Y; Rahmoune I; Filali H
Curr Drug Discov Technol; 2023; 20(4):e160423215830. PubMed ID: 37066770
[TBL] [Abstract][Full Text] [Related]
2. Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods.
Kulkarni AM; Kumar V; Parate S; Lee G; Yoon S; Lee KW
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163234
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.
Cheng J; Li Y; Wang X; Dong G; Sheng C
J Med Chem; 2020 Jul; 63(14):7892-7905. PubMed ID: 32603594
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Toxoplasma gondii virulence factor ROP18 competitive inhibitors by virtual screening.
Yin K; Zhao G; Xu C; Qiu X; Wen B; Sun H; Liu G; Liu Y; Zhao Q; Wei Q; Huang B; Yan G; Cao J
Parasit Vectors; 2019 Mar; 12(1):98. PubMed ID: 30867024
[TBL] [Abstract][Full Text] [Related]
6. Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation.
Raafat A; Mowafy S; Abouseri SM; Fouad MA; Farag NA
Comput Biol Med; 2022 Jul; 146():105526. PubMed ID: 35487125
[TBL] [Abstract][Full Text] [Related]
7. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
[TBL] [Abstract][Full Text] [Related]
8. Identification of pyrazolopyridazinones as PDEδ inhibitors.
Papke B; Murarka S; Vogel HA; Martín-Gago P; Kovacevic M; Truxius DC; Fansa EK; Ismail S; Zimmermann G; Heinelt K; Schultz-Fademrecht C; Al Saabi A; Baumann M; Nussbaumer P; Wittinghofer A; Waldmann H; Bastiaens PI
Nat Commun; 2016 Apr; 7():11360. PubMed ID: 27094677
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ.
Dharmaiah S; Bindu L; Tran TH; Gillette WK; Frank PH; Ghirlando R; Nissley DV; Esposito D; McCormick F; Stephen AG; Simanshu DK
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6766-E6775. PubMed ID: 27791178
[TBL] [Abstract][Full Text] [Related]
10. Identification of Potent Small-Molecule PCSK9 Inhibitors Based on Quantitative Structure-Activity Relationship, Pharmacophore Modeling, and Molecular Docking Procedure.
Mahmoudi A; Butler AE; Banach M; Jamialahmadi T; Sahebkar A
Curr Probl Cardiol; 2023 Jun; 48(6):101660. PubMed ID: 36841313
[TBL] [Abstract][Full Text] [Related]
11. Ligand-based pharmacophore detection, screening of potential gliptins and docking studies to get effective antidiabetic agents.
Agrawal R; Jain P; Dikshit SN
Comb Chem High Throughput Screen; 2012 Dec; 15(10):849-76. PubMed ID: 23140189
[TBL] [Abstract][Full Text] [Related]
12. Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products.
Gao Q; Wang Y; Hou J; Yao Q; Zhang J
J Comput Aided Mol Des; 2017 Jul; 31(7):625-641. PubMed ID: 28623487
[TBL] [Abstract][Full Text] [Related]
13. Structure-based pharmacophore modeling, virtual screening and simulation studies for the identification of potent anticancerous phytochemical lead targeting cyclin-dependent kinase 2.
Sharma M; Sharma N; Muddassir M; Rahman QI; Dwivedi UN; Akhtar S
J Biomol Struct Dyn; 2022; 40(20):9815-9832. PubMed ID: 34151738
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer.
Mohan A; Krishnamoorthy S; Sabanayagam R; Schwenk G; Feng E; Ji HF; Muthusami S
Eur J Pharmacol; 2023 Oct; 957():175961. PubMed ID: 37549730
[TBL] [Abstract][Full Text] [Related]
15. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L
Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potential FGFR3 inhibitors via QSAR, pharmacophore modeling, virtual screening and molecular docking studies against bladder cancer.
Ganji M; Bakhshi S; Shoari A; Ahangari Cohan R
J Transl Med; 2023 Feb; 21(1):111. PubMed ID: 36765337
[TBL] [Abstract][Full Text] [Related]
17. EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells.
Chen YH; Lv H; Shen N; Wang XM; Tang S; Xiong B; Ding J; Geng MY; Huang M
Acta Pharmacol Sin; 2020 Feb; 41(2):270-277. PubMed ID: 31316177
[TBL] [Abstract][Full Text] [Related]
18. Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity.
Lee J; Lee HJ; Lee Y; Lim B; Gam J; Oh DC; Lee J
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1656-1666. PubMed ID: 35695156
[TBL] [Abstract][Full Text] [Related]
19. Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches.
Jethwa M; Gangopadhyay A; Saha A
J Biomol Struct Dyn; 2023 Mar; 41(5):1681-1689. PubMed ID: 35014597
[TBL] [Abstract][Full Text] [Related]
20. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
